Home Cart Sign in  
Chemical Structure| 300816-15-3 Chemical Structure| 300816-15-3

Structure of RS 504393
CAS No.: 300816-15-3

Chemical Structure| 300816-15-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 98 nM and > 100 μM for inhibition of human recombinant CCR2b and CCR1 receptors respectively).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RS 504393

CAS No. :300816-15-3
Formula : C25H27N3O3
M.W : 417.50
SMILES Code : O=C1OC2(CCN(CCC3=C(C)OC(C4=CC=CC=C4)=N3)CC2)C5=CC(C)=CC=C5N1
MDL No. :MFCD09038564
InChI Key :ODNICNWASXKNNQ-UHFFFAOYSA-N
Pubchem ID :9953769

Safety of RS 504393

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of RS 504393

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SIM-A9 cells 100 µM 12 hours To evaluate the effect of RS504393 on ethanol-induced MCP-1/CCR2 signaling in SIM-A9 cells. Results showed that RS504393 significantly reduced ethanol-induced increase in MCP-1 expression. J Neuroinflammation. 2018 Jul 5;15(1):197.
Mouse dorsal root ganglion neurons 10 µM 3 minutes To evaluate the effect of CCR2 antagonist on TRPV1 sensitization, results showed that 10 μM RS 504393 significantly reduced the proportion of Berk SS neurons responding to 5 nM capsaicin Pain. 2018 Aug;159(8):1652-1663

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Ethanol-exposed developing brain model Subcutaneous injection 1 mg/kg Two injections, 24 hours and 0.5 hours prior to ethanol exposure To evaluate the effect of RS504393 on ethanol-induced neuroinflammation and neurodegeneration in the developing brain. Results showed that RS504393 significantly reduced ethanol-induced neuroapoptosis, microglial activation, and expression of pro-inflammatory cytokines. J Neuroinflammation. 2018 Jul 5;15(1):197.
Mice Bone cancer pain model Intrathecal administration 1-3 μg 5 administrations, 48, 36, 24, 12, and 1 hour before Inhibition of tumor-induced thermal hyperalgesia, reduction of astroglial activation in the superficial laminae of the spinal cord Cell Mol Neurobiol. 2014 Jan;34(1):143-56
Mice Unilateral ureteral obstruction model Oral 2 mg/kg Twice a day, starting from 3 days before ureteral ligation until the day of sacrifice To evaluate the therapeutic effects of RS-504393 on renal interstitial fibrosis, results showed that RS-504393 reduced renal interstitial fibrosis and macrophage infiltration Am J Pathol. 2004 Jul;165(1):237-46
Mice Pressure overload-induced heart failure model Subcutaneous injection 2 mg/kg Once daily for 1 or 6 weeks Blocking CCR2+ monocyte recruitment during pressure overload modified the proportion of macrophage subsets within the pathological heart and preserved lymphatic network from remodeling. Sci Rep. 2021 Aug 19;11(1):16801
CD1 mice Inflammatory pain model Intrathecal injection 20 μg Single dose RS504393 reversed CFA-induced heat hyperalgesia Neurosci Bull. 2018 Feb;34(1):13-21
Wistar rats Chronic constriction injury (CCI) model of the sciatic nerve Intrathecal injection 20 μg/5μl Preemptive administration at 16 h and 1 h before CCI, then once daily for 7 days RS504393 not only attenuated CCI-induced tactile and thermal hypersensitivity but also enhanced the analgesic effects of morphine and buprenorphine by reducing the mRNA and/or protein levels of pronociceptive factors such as IL-1beta, IL-18, IL-6, and iNOS in neuropathic pain. J Neuroimmune Pharmacol. 2017 Sep;12(3):402-419
Mice Berkeley sickle mice (Berk SS) Subcutaneous injection 3 mg/kg Single administration, 30 minutes prior to behavioral testing To evaluate the effect of CCR2 antagonist on mechanical and cold hypersensitivity in SCD mice, results showed that 3 mg/kg RS 504393 significantly alleviated mechanical and cold hypersensitivity in Berk SS mice Pain. 2018 Aug;159(8):1652-1663
C57BL/6J male mice Subarachnoid hemorrhage model Intraperitoneal injection 3 mg/kg/day Once daily for 24 hours To investigate the effects of RS504393 on neurological deficits, brain edema, blood-brain barrier permeability, neuroinflammation, and neuronal apoptosis after SAH. Results showed that RS504393 significantly improved neurological scores, reduced brain edema and BBB disruption, and decreased the expression of inflammatory and apoptotic factors. J Neuroinflammation. 2022 Dec 25;19(1):312
DBA mice Collagen-induced arthritis model Intraperitoneal injection 4 mg/kg Every 48 hours for 2 weeks To evaluate the effect of CCR2 SMI on arthritis development, results showed CCR2 SMI alone or in combination with MTX reduced bone resorption and OCP frequency Front Immunol. 2021 Dec 3;12:767231
Mice Destabilization of the medial meniscus (DMM) surgery-induced osteoarthritis model Oral gavage 4 mg/kg/day Once daily for 12 weeks To evaluate the effect of RS-504393 on the development of osteoarthritis in mice. Results showed that RS-504393 significantly attenuated cartilage damage, synovitis, and osteophyte formation, and reduced the accumulation of F4/80+ macrophages in the synovium. Ann Rheum Dis. 2017 May;76(5):914-922.
Mice Destabilization of medial meniscus (DMM) model Oral 4mg/kg/day Once daily for 1-4 weeks, 4-8 weeks, or 8-12 weeks Early CCR2 blockade (1-4 weeks) significantly reduced cartilage and bone damage and alleviated pain responses; delayed treatment was less effective. Osteoarthritis Cartilage. 2017 Jun;25(6):914-925

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

11.98mL

2.40mL

1.20mL

23.95mL

4.79mL

2.40mL

References

 

Historical Records

Categories